

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5486319

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH	09/27/2018
RECEIVING PARTY DATA	
Name:	THE SCRIPPS RESEARCH INSTITUTE
Street Address:	10550 NORTH TORREY PINES ROAD
City:	LA JOLLA
State/Country:	CALIFORNIA
Postal Code:	92037
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16343353
CORRESPONDENCE DATA	
Fax Number:	(202)842-7899
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2028427800
Email:	zIPPatentDocketingMailboxUS@cooley.com, steven.erickson@cooley.com
Correspondent Name:	COOLEY LLP
Address Line 1:	1299 PENNSYLVANIA AVE NW, SUITE 700
Address Line 2:	ATTN: PATENT DEPARTMENT/ AARON NUDELMAN
Address Line 4:	WASHINGTON, D.C. 20004
ATTORNEY DOCKET NUMBER:	TSRI-011/01US 191755-2060
NAME OF SUBMITTER:	AARON S. NUDELMAN, PH.D.
SIGNATURE:	/Aaron S. Nudelman/
DATE SIGNED:	04/22/2019
Total Attachments: 12	
source=TSRI-011_01US-Assignment-CALIBR_to_SCRIPPS w schedule A-executed#page1.tif	
source=TSRI-011_01US-Assignment-CALIBR_to_SCRIPPS w schedule A-executed#page2.tif	
source=TSRI-011_01US-Assignment-CALIBR_to_SCRIPPS w schedule A-executed#page3.tif	
source=TSRI-011_01US-Assignment-CALIBR_to_SCRIPPS w schedule A-executed#page4.tif	

source=TSRI-011_01US-Assignment-CALIBR_to_SCRIPPS w schedule A-executed#page5.tif
source=TSRI-011_01US-Assignment-CALIBR_to_SCRIPPS w schedule A-executed#page6.tif
source=TSRI-011_01US-Assignment-CALIBR_to_SCRIPPS w schedule A-executed#page7.tif
source=TSRI-011_01US-Assignment-CALIBR_to_SCRIPPS w schedule A-executed#page8.tif
source=TSRI-011_01US-Assignment-CALIBR_to_SCRIPPS w schedule A-executed#page9.tif
source=TSRI-011_01US-Assignment-CALIBR_to_SCRIPPS w schedule A-executed#page10.tif
source=TSRI-011_01US-Assignment-CALIBR_to_SCRIPPS w schedule A-executed#page11.tif
source=TSRI-011_01US-Assignment-CALIBR_to_SCRIPPS w schedule A-executed#page12.tif

PATENT ASSIGNMENT

This PATENT ASSIGNMENT (this “**Assignment**”), dated as of October 1, 2018 (the “**Effective Date**”), is made by and between The California Institute for Biomedical Research, a California non-profit public benefit corporation, with offices at 11119 North Torrey Pines Road, Suite 100, La Jolla, CA 92037 (“**Assignor**”) and The Scripps Research Institute, a California non-profit public benefit corporation, with offices at 10550 North Torrey Pines Road, La Jolla, CA 92037 (“**Assignee**”).

For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

1. **Assignment.** Assignor hereby transfers, conveys and assigns to Assignee, its successors and assigns, all of Assignor’s rights, title and interests in and under any and all national, regional and international patents and patent applications, including provisional patent applications, in each case, that are listed on the attached Schedule A, and inventions embodied therein, together with all: (a) patent applications filed either from such patents, patent applications or provisional applications or from an application claiming priority from either of these, including divisionals, continuations, continuations-in-part, provisionals, converted provisionals and continued prosecution applications; (b) patents that have issued or in the future issue from the foregoing patent applications including utility models, industrial design and design patents and certificates of invention; (c) extensions or restorations by existing or future extension or restoration mechanisms, including revalidations, reissues, re-examinations and extensions (including any supplementary protection certificates, patent term extensions, patent term adjustments and the like) of the foregoing patents or patent applications; and (d) any importation, revalidation, confirmation or introduction patent or registration patent or patent of additions to any of such foregoing patent applications and patents (hereinafter, collectively, the “**Assigned Patents**”).
2. **Further Conveyance.** Assignor hereby transfers, conveys, and assigns to Assignee, its successors and assigns, all of Assignor’s rights to sue or to bring any action or to assert any claim, whether at law or in equity, against any third party relating to any of the Assigned Patents, including without limitation for past, present or future infringement, misappropriation, or other unauthorized use or misuse of any of the Assigned Patents, to obtain injunctive relief, and to recover or collect royalties, damages, and profits, including without limitation for such past, present or future infringement, misappropriation or unauthorized use or misuse of any of the Assigned Patents.
3. **Authorization and Request.** Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and empowered officials and all other governments, to issue or transfer any and all of the Assigned Patents to said Assignee, for Assignee’s full use and enjoyment and for the use and enjoyment of Assignee’s legal representatives, successors and assigns, to the full end of the term for which the Assigned Patents may be granted, as fully and entirely as the same would have been held by Assignor had this Assignment not been made.
4. **Cooperation; Appointment.** Assignor, at Assignee’s expense, hereby agrees to prepare, execute and, if requested by Assignor, have notarized any further intellectual property assignments required to transfer the Assigned Patents to Assignee. Assignor hereby designates and appoints Assignee and its duly authorized officers and agents as its agents and attorneys in fact, to act for and in its behalf and stead to execute and file any such documents and to do all other lawfully permitted acts to register, evidence or perfect Assignee’s rights under this Assignment, with the same legal force and effect as if executed by Assignor or any of its successors, legal representatives or assigns.
5. **No Conflicts.** Assignor hereby covenants and agrees that it will not execute any agreement in conflict herewith.

6. Amendments. This Assignment shall not be amended, modified or supplemented except by a written instrument signed by an authorized representative of each of Assignor or Assignee.
7. Successors and Assigns. This Assignment shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and permitted assigns.
8. Governing Law. This Assignment and any claim, controversy, dispute or cause of action (whether in contract, tort or otherwise) based upon, arising out of or relating to this Assignment and the transactions contemplated hereby shall be governed by, and construed in accordance with, the laws of the United States and the State of California, without giving effect to any choice or conflict of law provision or rule.
9. Counterparts. This Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Assignment delivered by e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Assignment.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties hereto have caused their duly authorized representatives to execute and deliver this Assignment as of the date first above written.

ASSIGNOR:

THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH

By: Kelly San George
Name: Kelly San George
Title: Chief Financial Officer

ASSIGNEE:

THE SCRIPPS RESEARCH INSTITUTE

By: Jared Machado
Name: Jared Machado
Title: Chief Financial Officer

A Notary Public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California


) ss

County of San Diego

On September 27, 2018 before me, Bethany M. Crandell, Notary Public, personally appeared Kelly San George and Jared Machado who proved to me on the basis of satisfactory evidence to be the persons whose names are subscribed to the within instrument and acknowledged to me that they executed the same in their authorized capacities, and that by their signatures on the instrument the persons, or the entity upon behalf of which the persons acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.



Bethany M. Crandell
Notary Public

[Signature Page to Patent Assignment]

SCHEDULE A
ASSIGNED PATENTS

TSRI Ref. No.	Application No.	Filing Date	Patent No.	Issued	Country	Title
1603.0 P	61/827,539	5/23/2013			US	COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS
1603.1 P	61/950,752	3/10/2014			US	COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS
1603.2 PC	14/039227	5/22/2014	WO 14/0190199	11/27/2014	PCT	COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS
1603.2 US	14/893,465	11/23/2015	-	-	US	COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS
1604.0 P	61/751,598	1/11/2013	-	-	US	BOVINE FUSION ANTIBODIES
1604.1	14/152,441	1/10/2014	9,644,021	5/9/2017	US	BOVINE FUSION ANTIBODIES
1604.1 PC	14/011043	1/10/2014	WO 14/110368	7/17/2014	PCT	BOVINE FUSION ANTIBODIES
1604.1 US	14/760,115	7/9/2015	-	-	US	BOVINE FUSION ANTIBODIES
1605.0 P	61/783,426	3/14/2013	-	-	US	BISPECIFIC ANTIBODIES AND USES THEREOF
1605.1 P	61/839,330	6/25/2013	-	-	US	BISPECIFIC ANTIBODIES AND USES THEREOF
1605.2 PC	14/029379	3/14/2014	WO 14/0153164	9/25/2014	PCT	TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF
1605.2 US	14/774,647	9/10/2015	-	-	US	TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF
1605.2 CON 1	15/268,389	9/16/2016	-	-	US	TARGETING AGENT ANTIBODY CONJUGATES AND USES THEREOF
1605.3 PC	14/028612	3/14/2014	WO 14/153002	9/25/2014	PCT	BI-SPECIFIC ANTIBODIES AND USES THEREOF
1605.3 US	14/774,649	9/10/2015	-	-	US	BISPECIFIC ANTIBODIES AND USES THEREOF
1606.0 P	61/794,094	3/15/2013	-	-	US	COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS

TSRI Ref. No.	Application No.	Filing Date	Patent No.	Issued	Country	Title
1606.1	14/210,198	3/13/2014	9,452,170	9/27/2016	US	COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS
1606.1 PC	14/026722	3/13/2014	WO 14/151953	9/25/2014	PCT	COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS
1606.1 US	14/774,673	9/10/2015	-	-	US	COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS
1607.0 P	61/832,768	6/7/2013			US	SMALL MOLECULE INHIBITORS OF FIBROSIS
1607.1 PC	14/041174	6/5/2014	WO 14/197738	12/11/2014	PCT	SMALL MOLECULE INHIBITORS OF FIBROSIS
1607.1 US	14/895,813	12/3/2015	9,663,499	5/30/2017	US	SMALL MOLECULE INHIBITORS OF FIBROSIS
1607.1 DIV 1	15/488,206	4/14/2017	9,981,956	5/29/2018	US	SMALL MOLECULE INHIBITORS OF FIBROSIS
1666.0 P	61/891,347	10/15/2013	-	-	US	METHODS OF PRODUCING SWITCHABLE CHIMERIC ANTIGEN RECEPTOR T CELLS AND USES THEREOF
1666.1 P	61/895,704	10/25/2013	-	-	US	METHODS OF PRODUCING SWITCHABLE CHIMERIC ANTIGEN RECEPTOR T CELLS AND USES THEREOF
1666.2 P	62/009,056	6/6/2014	-	-	US	CHIMERIC ANTIGEN RECEPTOR T CELLS AND USES THEREOF
1666.4 PC	14/060713	10/15/2014	WO 15/057852	4/23/2015	PCT	CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF
1666.4 US	14/432,065	3/27/2015	-	-	US	CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF
1666.4 CON 1	15/363,350	11/29/2016	-	-	US	CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF
1666.4 CON 2	15/644,657	7/7/2017	-	-	US	CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF
1666.5 PC	14/060684	10/15/2014	WO 15/057834	04/23/2015	PCT	PEPTIDIC CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF
1666.6	14/688,894	4/16/2015	9,624,276	4/18/2017	US	PEPTIDIC CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF

TSRI Ref. No.	Application No.	Filing Date	Patent No.	Issued	Country	Title
1666.6 CON 1	15/448,477	3/2/2017	-	-	US	PEPTIDIC CHIMERIC ANTIGEN RECEPTOR T CELL SWITCHES AND USES THEREOF
1667.0 P	61/845,280	7/11/2013			US	METHODS OF CONSTRUCTING IMMUNOGLOBULIN BETA STRAND FUSION PROTEINS AND COMPOSITIONS THEREOF
1667.1 P	61/845,287	7/11/2013			US	METHODS OF CONSTRUCTING IMMUNOGLOBULIN BETA STRAND FUSION PROTEINS AND COMPOSITIONS THEREOF
1667.2 P	61/925,904	1/10/2014			US	METHODS OF CONSTRUCTING IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF
1667.3 P	62/017,713	6/26/2014			US	METHODS OF CONSTRUCTING IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF
1667.4 PC	14/046429	7/11/2014	WO 15/006744	1/15/2015	PCT	IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF
1667.4 US	14/903,489	1/7/2016	-	-	US	IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF
1667.5 PC	14/046419	7/11/2014	WO 15/006736	1/15/2015	PCT	OILED COIL IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF
1667.5 US	14/903,492	1/7/2016	-	-	US	COILED COIL IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF
1681.00 P	62/009,054	6/6/2014	-	-	US	CONSTANT REGION ANTIBODY FUSION PROTEINS AND COMPOSITIONS THEREOF
1681.0 P	62/030,514	7/29/2014	-	-	US	MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
1681.1 P	62/064,199	10/15/2014	-	-	US	CONSTANT REGION ANTIBODY FUSION PROTEINS AND COMPOSITIONS THEREOF
1681.2 PC	15/034541	6/5/2015	WO 15/188135	12/10/2015	PCT	CONSTANT REGION ANTIBODY FUSION

TSRI Ref. No.	Application No.	Filing Date	Patent No.	Issued	Country	Title
						PROTEINS AND COMPOSITIONS THEREOF
1681.2US	15/315,641	12/02/2016			US	CONSTANT REGION ANTIBODY FUSION PROTEINS AND COMPOSITIONS THEREOF
1682.0 P	61/877,799	9/13/2013			US	MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
1682.1 P	61/917,816	12/18/2013			US	MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
1682.2 PC	14/055457	9/12/2014	WO 15/038938	3/19/2015	PCT	MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
1682.2 US	14/917,689	3/9/2016	-	-	US	MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
1684.0 P	61/917,816	12/18/2013			US	MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF
1684.1 PC	14/070977	12/17/2014	WO 15/095406	6/25/2015	PCT	MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF
1684.1 US	15/104,807	6/15/2016	10,039,809	8/7/2018	US	MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF
1684.1 CON 1	16/000,829	6/5/2018	-	-	US	MODIFIED THERAPEUTIC AGENTS, STAPLED PEPTIDE LIPID CONJUGATES, AND COMPOSITIONS THEREOF
1687.0 P	62/090,267	12/10/2014	-	-	US	SMALL MOLECULE INHIBITORS OF FIBROSIS
1687.1 P	62/117,846	2/18/2015	-	-	US	SMALL MOLECULE INHIBITORS OF FIBROSIS
1687.2 PC	15/064814	12/9/2015	WO 16/094570	6/16/2016	PCT	SMALL MOLECULE INHIBITORS OF FIBROSIS
1687.2 US	15/534,225	6/8/2017	-	-	US	SMALL MOLECULE INHIBITORS OF FIBROSIS
1707.0 P	62/030,526	7/29/2014	-	-	US	METHODS OF CONSTRUCTING AMINO TERMINAL IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF
1707.1 P	62/064,186	10/15/2014	-	-	US	AMINO TERMINAL IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF

TSRI Ref. No.	Application No.	Filing Date	Patent No.	Issued	Country	Title
1707.2 PC	15/034533	6/5/2015	WO 15/188132	1/12/2017	PCT	AMINO TERMINAL IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF
1707.2 US	15/315,645	12/1/2016	-	-	US	AMINO TERMINAL IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF
1771.0 P	62/148,070	4/15/2015	-	-	US	CHIMERIC RECEPTOR T CELL SWITCHES FOR HER2
1771.1 P	62/253,465	11/10/2015	-	-	US	CHIMERIC RECEPTOR T CELL SWITCHES FOR HER2
1771.2 PC	16/027993	4/15/2016	WO 16/168769	10/20/2016	PCT	CHIMERIC RECEPTOR T CELL SWITCHES FOR HER2
1771.3 PC	16/027990	4/15/2016	WO 16/168766	10/20/2016	PCT	OPTIMIZED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF
1771.3 US	15/566,685	4/15/2016	-	-	US	OPTIMIZED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF
1850.0 P	62/633,409	2/21/2018	-	-	US	AGONISTS OF STIMULATOR OF INTERFERON GENES STING
1861.0 P	62/248,866	10/30/2015			US	OXYNTOMODULIN ANALOGS AND METHODS OF MAKING AND USE SAME
1861.1	15/451,503	3/7/2017	9,931,379	4/3/2018	US	OXYNTOMODULIN ANALOGS AND METHODS OF MAKING AND USING SAME
1861.1PC	16/059705	10/30/2015	WO 17/075583	5/4/2017	PCT	OXYNTOMODULIN ANALOGS AND METHODS OF MAKING AND USING SAME
1861.1US	15/451,503	3/7/23017	9,931,379	4/3/2018	US	OXYNTOMODULIN ANALOGS AND METHODS OF MAKING AND USING SAME
1884.0 P	61/842,300	7/2/2013			US	COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS
1884.1 P	61/969,737	3/23/2013			US	COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS
1884.2 PC	14/045301	7/2/2014	WO 15/003083	1/18/2015	PCT	COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS
1884.2 US	14/900,355	12/21/2015	9,656,972	5/23/2017	US	COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS

TSRI Ref. No.	Application No.	Filing Date	Patent No.	Issued	Country	Title
1886.1 PC	15/032275	5/22/2015	WO 15/179823	5/19/2016	PCT	LUNG LOCALIZED INHIBITORS OF ALPHA(V)BETA6
1887.1 PC	15/37229	6/23/2015	WO 15/200349	12/30/2015	PCT	ELASTASE INHIBITORS
1887.1 US	15/381,507	12/16/2016	-	-	US	ELASTASE INHIBITORS
1890.1 PC	16/012360	1/6/2016	-	-	PCT	COMPOUNDS FOR TREATMENT OF CYSTIC FIBROSIS
1891.1 PC	16/015409	1/28/2016	-	-	PCT	METHODS OF ANTIBIOTIC TREATMENT WITH METAL-THIOLATE COMPLEXES
1892.0 P	62/134,939	3/18/2015	-	-	US	MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
1892.1 PC	16/022880	3/17/2016	WO 16/0149501	9/22/2016	PCT	MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
1892.1 US	15/557,986	9/13/2017	-	-	US	MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
1893.0 P	62/141,763	4/1/2015	-	-	US	METHODS FOR TREATING VIRAL INFECTIONS
1893.1 PC	16/025364	3/31/2016	WO 16/161176	10/6/2016	PCT	METHODS FOR TREATING VIRAL INFECTIONS
1893.1 US	15/562,788	9/28/2017	-	-	US	METHODS FOR TREATING VIRAL INFECTIONS
1894.0 P	62/158,726	5/8/2015	-	-	US	LIVER X RECEPTOR AGONISTS AND USES THEREOF
1894.1	15/147,863	5/5/2016	-	-	US	LIVER X RECEPTOR AGONISTS AND USES THEREOF
1895.0 P	62/180,856	6/17/2015	-	-	US	MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
1895.1 PC	16/037834	6/16/2016	WO2016/205488	12/22/2016	PCT	MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
1895.1 US	15/735,898	12/12/2017	-	-	US	MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
1896.0 P	62/184,813	6/25/2015	-	-	US	MST1 INHIBITORS
1896.1 PC	16/039388	6/24/2016	WO 16/210345	12/29/2016	PCT	MST1 INHIBITORS
1896.1 US	15/738,986	12/21/2017	-	-	US	MST1 INHIBITORS
1898.0 P	62/192,768	7/15/2015	-	-	US	AURISTATIN-ANTIBODY CONJUGATES AND USES THEREOF

TSRI Ref. No.	Application No.	Filing Date	Patent No.	Issued	Country	Title
1898.1	15/210,729	7/14/2016	-	-	US	AURISTATIN-ANTIBODY CONJUGATES AND USES THEREOF
1899.0 P	62/214,605	9/4/2015			US	INSULIN IMMUNOGLOBULIN FUSION PROTEINS
1899.1 PC	16/050213	9/2/2016	WO 17/041001	3/9/2017	PCT	INSULIN IMMUNOGLOBULIN FUSION PROTEINS
1899.1 US	15/756,296	2/28/2018	-	-	US	INSULIN IMMUNOGLOBULIN FUSION PROTEIN
1900.0P	62/515,282	6/05/2017			US	APOLIPOPROTEIN C-III INHIBITION
1901.0 P	62/204,120	8/12/2015	-	-	US	LPA MODULATORS FOR BROWN FAT DIFFERENTIATION
1901.1	15/234,994	8/11/2016	-	-	US	LPA MODULATORS FOR BROWN FAT DIFFERENTIATION
1903.0 P	62/265,344	12/9/2015			US	METHODS OF CONSTRUCTING IMMUNOGLOBULIN FUSION PROTEINS AND COMPOSITIONS THEREOF
1903.1 PC	16/065779	12/9/2016	WO 17/100540	6/15/2017	PCT	RELAXIN IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF USE
1903.1US	16/060,384	6/07/2018			US	RELAXIN IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF USE
1906.0 P	62/291,143	2/4/2016	-	-	US	HUMANIZED ANTI-CD3 ANTIBODIES, CONJUGATES AND USES THEREOF
1906.1 PC	17/016407	2/3/2017	WO 17/136659	9/8/2017	PCT	HUMANIZED ANTI-CD3 ANTIBODIES, CONJUGATES AND USES THEREOF
1906.1US	16/074,600	8/01/2018			US	HUMANIZED ANTI-CD3 ANTIBODIES, CONJUGATES AND USES THEREOF
1908.0 P	62/352,455	6/20/2016			US	ANTIMALARIAL COMPOSITIONS AND USES THEREOF
1908.1 PC	17/038173	6/19/2017	WO 17/222996	12/28/2017	PCT	ANTIMALARIAL COMPOSITIONS AND USES THEREOF
1909.0 P	62/342,720	5/27/2016	-	-	US	PEPTIDE CONJUGATES AND USES THEREOF
1912.3 PC	17/041376	7/10/2017	WO 18/013483	1/18/2018	PCT	KV1.3 CHANNEL BLOCKING ANTIBODIES AND USES THEREOF

TSRI Ref. No.	Application No.	Filing Date	Patent No.	Issued	Country	Title
1913.0 P	62/415,287	10/31/2016			US	METHODS AND COMPOSITIONS FOR PREVENTING VECTOR-BORNE DISEASE TRANSMISSION
1913.1 PC	17/059084	10/30/2017	-	-	PCT	METHODS AND COMPOSITIONS FOR PREVENTING VECTOR-BORNE DISEASE TRANSMISSION
1914.2 PC	17/054768	10/2/2017	-	-	PCT	COMPOSITIONS AND METHODS FOR TREATING DRUG-RESISTANT BACTERIA
1918.1PC	18/28939	4/23/2018			PCT	METHODS FOR INDUCING CHONDROGENESIS
1920.2 PC	15/053745	10/2/2015	WO 16/054520	4/7/2016	PCT	CHIMERIC ANTIGEN RECEPTOR T CELLS AND USES THEREOF
1922.0 P	62/138,901	3/26/2015			US	SWITCHABLE NON-scFv CHIMERIC RECEPTOR T CELLS AND USES THEREOF
1922.1 PC	16/024524	3/28/2016	WO 16/154621	9/29/2016	PCT	SWITCHABLE NON-scFv CHIMERIC RECEPTOR T CELLS AND USES THEREOF
1922.1 US	15/561,274	3/28/2016	-	-	US	SWITCHABLE NON-scFv CHIMERIC RECEPTOR T CELLS AND USES THEREOF
1923.0 P	62/148,063	4/15/2015			US	OPTIMIZED CHIMERIC RECEPTOR CELL SWITCHES AND USES THEREOF
1923.1 P	62/253,467	11/10/2015			US	CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF
1923.2 PC	16/027997	4/15/2016	WO 16/168773	10/20/2016	PCT	OPTIMIZED PNE-BASED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF
1923.2US	15/566,680	10/13/2017			US	OPTIMIZED PNE-BASED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF
1924.1 PC	17/057460	10/19/2017	WO 18/075807	4/26/2018	PCT	CHIMERIC ANTIGEN RECEPTOR EFFECTOR CELL SWITCHES WITH HUMANIZED TARGETING MOIETIES AND/OR OPTIMIZED CHIMERIC ANTIGEN RECEPTOR INTERACTING DOMAINS AND USES THEREOF

TSRI Ref. No.	Application No.	Filing Date	Patent No.	Issued	Country	Title
1933.OP	62/727,133	9/5/2018				ACTIVATORS OF THE ANTIOXIDANT RESPONSE ELEMENT SIGNALING PATHWAY

80878218v.3

RECORDED: 03/13/2019

RECORDED: 04/22/2019

PATENT
REEL: 048590 FRAME: 0074

PATENT
REEL: 048959 FRAME: 0973